trial

Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment

NCTId NCT06881810
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Recruiting
Enrollment 98 (estimated)
Sponsored by Central Institute of Mental Health, Mannheim
Primary completion 2028-03-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Recruiting
Enrollment
98 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2024-08-29
Primary completion
2028-03-31
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
Oxytocin nasal spray

Sponsors

Central Institute of Mental Health, MannheimLead Sponsor

Investigators

1
Dusan Hirjak, Prof. Dr.Principal Investigator

Sites

1 total
Mannheim, Germany

Linked catalysts

1
Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on — primary completion2028-03-31

Facts & assertions

4 sourced
Enrollment
98
Phase
PHASE2
Primary Completion Date
2028-03-31
Status
RECRUITING
relationships
The graph out of here
drug
Oxytocin nasal spray
drug
lead_sponsor
Central Institute of Mental Health, Mannheim
company
indication
Schizophrenia Spectrum Disorders (SSD)
indication
investigator
Dusan Hirjak, Prof. Dr.
person